Literature DB >> 30746239

Evaluation of lobar lymph node metastasis in non-small cell lung carcinoma using modified total lesion glycolysis.

Hitoshi Dejima1,2, Hiroaki Kuroda1, Yuko Oya3, Noriaki Sakakura1, Yoshitaka Inaba4, Tsuneo Tamaki5, Yasushi Yatabe2, Yukinori Sakao1.   

Abstract

BACKGROUND: Volumetric parameters based on 3-dimensional reconstruction have recently been introduced for cancer staging. We aimed to improve the ability to diagnose hilar lymph node metastasis in patients with non-small cell lung cancer.
METHODS: We evaluated 142 patients with non-small cell lung cancer who underwent right upper lobectomy and radical lymph node dissection. Metastatic involvement of right upper lobar lymph nodes was assessed using high-resolution computed tomography (HRCT) and 18F-2-floro-2-deoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT).
RESULTS: On receiver operating characteristic (ROC) curve analysis, the area under the curves (AUC) for short axis, maximum of standardized uptake value (SUVmax), total lesion glycolysis (TLG) and modified TLG (mTLG) were 0.79, 0.77, 0.76, and 0.87, respectively. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of mTLG, using the optimal cut off value (2.45), for diagnosis of lobar lymph node metastasis were 71%, 88%, 44%, and 96%, respectively. Hilar asymmetric uptake (HAU) of FDG was larger in true-positive cases than in false-negative cases (P<0.01). Furthermore, the size of metastatic foci in the lymph node was smaller in false-negative cases (P=0.012).
CONCLUSIONS: Modified TLG is a good parameter to diagnose metastatic right upper lobar lymph nodes. Micrometastasis in the lymph node is difficult to predict using the current diagnostic method. However, more careful evaluation is required in patients with symmetric FDG accumulation at hilar region because hilar lymph nodes respond to various causes such as benign pulmonary diseases.

Entities:  

Keywords:  Total lesion glycolysis (TLG); hilar lymph node; lymph node metastasis; positron emission tomography/computed tomography (PET/CT); sublobar resection

Year:  2018        PMID: 30746239      PMCID: PMC6344716          DOI: 10.21037/jtd.2018.11.40

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  22 in total

1.  Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.

Authors:  Naoko Ose; Noriyoshi Sawabata; Masato Minami; Masayoshi Inoue; Yasushi Shintani; Yoshihisa Kadota; Meinoshin Okumura
Journal:  Eur J Cardiothorac Surg       Date:  2012-01-18       Impact factor: 4.191

Review 2.  Partial-volume effect in PET tumor imaging.

Authors:  Marine Soret; Stephen L Bacharach; Irène Buvat
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

3.  Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases.

Authors:  Romano Demicheli; Marco Fornili; Federico Ambrogi; Kristin Higgins; Jessamy A Boyd; Elia Biganzoli; Chris R Kelsey
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

4.  Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions.

Authors:  Chih-Ying Liao; Jin-Hua Chen; Ji-An Liang; Jun-Jun Yeh; Chia-Hung Kao
Journal:  Eur J Radiol       Date:  2012-03-19       Impact factor: 3.528

5.  Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients.

Authors:  Kazuya Takamochi; Junji Yoshida; Koji Murakami; Seiji Niho; Genichiro Ishii; Mitsuyo Nishimura; Yutaka Nishiwaki; Kazuya Suzuki; Kanji Nagai
Journal:  Lung Cancer       Date:  2005-02       Impact factor: 5.705

6.  Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications.

Authors:  Jiro Okami; Masahiko Higashiyama; Hisao Asamura; Tomoyuki Goya; Yoshihiko Koshiishi; Yasunori Sohara; Kenji Eguchi; Masaki Mori; Yoichi Nakanishi; Ryosuke Tsuchiya; Etsuo Miyaoka
Journal:  J Thorac Oncol       Date:  2009-10       Impact factor: 15.609

7.  Diagnostic performance of (18)F-FDG PET/CT for lymph node staging in patients with operable non-small-cell lung cancer and inflammatory lung disease.

Authors:  Young-Sil An; Joo Sung Sun; Kyung Joo Park; Sung Chul Hwang; Kwang Joo Park; Seung Soo Sheen; Sungsoo Lee; Kyi Beom Lee; Joon-Kee Yoon
Journal:  Lung       Date:  2008-08-01       Impact factor: 2.584

8.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.

Authors:  Christophe Van de Wiele; Vibeke Kruse; Peter Smeets; Mike Sathekge; Alex Maes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

9.  The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer.

Authors:  Hiroaki Nomori; Kenichi Watanabe; Takashi Ohtsuka; Tsuguo Naruke; Keiichi Suemasu; Kimiichi Uno
Journal:  J Thorac Cardiovasc Surg       Date:  2004-04       Impact factor: 5.209

10.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography.

Authors:  R Kubota; S Yamada; K Kubota; K Ishiwata; N Tamahashi; T Ido
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

View more
  2 in total

1.  Wedge resection, segmentectomy or lobectomy: the correct choice considering the risk of lobar lymph node involvement.

Authors:  Marco Chiappetta; Elisa Meacci; Dania Nachira; Leonardo Petracca Ciavarella; Stefano Margaritora
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

2.  Improving accuracy of hilar and lobar nodal staging in non-small cell lung cancer.

Authors:  Juha Kauppi; Jari Räsänen
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.